Phase II Evaluation of Cytembena (NSC-104801) in Patients With Advanced Ovarian Carcinoma Resistant to Alkylating Agents: Brief Communication

Seventeen patients with stages III and IV alkylating agent-resistant ovarian carcinomas were treated with cytembena, which was given in doses of 200 mg/m2 twice daily for 5 consecutive days every 5 weeks. Sixteen patients completed at least one course of treatment; 11 of them experienced objective p...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1977-12, Vol.59 (6), p.1619-1620
Main Authors: Edmonson, J. H., Decker, D. G., Malkasian, G. D., Webb, M. J., Jorgensen, E. O.
Format: Article
Language:English
Subjects:
Acrylates - adverse effects
Acrylates - therapeutic use
Alkylating Agents - therapeutic use
Drug Evaluation
Drug Resistance
Female
Humans
Nausea - chemically induced
Ovarian Neoplasms - drug therapy
Recurrence
Vomiting - chemically induced
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Seventeen patients with stages III and IV alkylating agent-resistant ovarian carcinomas were treated with cytembena, which was given in doses of 200 mg/m2 twice daily for 5 consecutive days every 5 weeks. Sixteen patients completed at least one course of treatment; 11 of them experienced objective progression of disease or failed to continue treatment because of a continuing symptomatic deterioration within the first two treatment cycles. Three patients remained objectively stable after two courses of treatment, but were symptomatically worse and stopped treatment for that reason. Another patient experienced progression after three courses, and the final patient voluntarily withdrew after three courses. No objective regression of disease occurred during treatment with cytembena. Nausea and vomiting occurred at some time in all except 1 patient, and 3 patients experienced mild diarrhea. Two patients had alopecia.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/59.6.1619